Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by targeting of anagen hair follicles by the host immune system, resulting in nonscarring hair loss but preservation of hair follicles. Topical corticosteroids and topical contact allergens are commonly prescribed for AA; however, AA treatment guidelines are sparse, as is clinical evidence supporting the efficacy of current therapies. Biologics and Janus kinase (JAK) inhibitors have demonstrated efficacy in the treatment of AA, but long-term safety and efficacy trials are needed to assess these agents’ risk-benefit profiles.
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed AA patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed AA patients?
- How have topical and injectable corticosteroids been integrated into the treatment algorithm, and what is their source of business? Do JAK inhibitors (e.g., Incyte’s Jakafi, Eli Lilly’s Olumiant) and biologics (Sanofi’s Dupixent) experience off-label use in AA?
- What percentage of AA patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of AA patients are treated with monotherapy versus combination therapy? What are the most commonly used drug combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
- Geography: United States
- Real-world data: Longitudinal patient-level claims data analysis
- Key drugs covered: Stelara, Dupixent, Xeljanz, Jakafi, Olumiant, Eucrisa, Elidel
- Key analysis provided: brand/therapy usage across longitudinal patient sample, newly diagnosed patient analysis, treatment initiation and progression, line of therapy analysis, combination therapy analysis, source of business for recently treated patients, persistency and compliance analysis, product-level patient flowcharts
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, so you can accurately assess your source of business, benchmark usage against competitors, and quantify areas of opportunity for your marketed or emerging brand.
- Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)
- Treatment Algorithms Claims Data Analysis Alopecia Areata US March 2020
Author(s): Sonal Divekar
Sonal Divekar is a analyst on DRG’s Infectious, Niche & Rare Diseases team, covering diverse indications across the niche & rare portfolio. Prior to this role, she was working as a Senior Analyst at Merck’s Global Centre for Analytics and Forecasting. Her role focused on creating Long Range Forecasts and Demand Forecasts for therapeutic areas like Diabetes and Immunology for the European market. She holds a Master’s degree in Marketing Management from Symbiosis Institute of Business Management, India and a Master’s degree in Microbiology from Pune University, India.